Literature DB >> 10867616

Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers.

A Nicolini1, A Carpi.   

Abstract

The role of serial measurement of serum tumor-associated antigens (TAA) in the postoperative follow-up of breast cancer patients is not considered by most authors. The authors of this article review the literature and original data showing benefits from the use of TAA in the postoperative follow-up of breast cancer patients. An increase in the lead time from the first pathological finding to the definite evidence of distant metastases has been observed in follow-up studies which have used TAA compared to those which did not use them. The sensitivity and specificity of TAA in the diagnosis of distant metastases have been markedly improved by selecting an appropriate combination of TAA and by identifying specific conditions associated with breast cancer responsible for false-positive results as well as by adopting a 'dynamic' evaluation of multiple successive determinations of TAA. TAA accurately predict patients with bone metastases and can be used to guide imaging techniques. The anticipation of distant metastasis by TAA can be used to initiate a relatively early treatment which has been shown to prolong overall survival in a previous study. It is hoped that these data will stimulate further trials including TAA in the follow-up of breast cancer patients. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867616     DOI: 10.1159/000030129

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

1.  Multiplexed cancer biomarker detection using quartz-based photonic crystal surfaces.

Authors:  Cheng-Sheng Huang; Vikram Chaudhery; Anusha Pokhriyal; Sherine George; James Polans; Meng Lu; Ruimin Tan; Richard C Zangar; Brian T Cunningham
Journal:  Anal Chem       Date:  2011-12-29       Impact factor: 6.986

2.  A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma.

Authors:  Meera S Ghadge; Purva P Naik; Bijaynath P Tiwari; Ruprekha M Hegde; Tanaji J Matale
Journal:  Indian J Clin Biochem       Date:  2011-09-30

3.  Analysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.

Authors:  Roshni Gavel; S P Mishra; Seema Khanna; Rahul Khanna; Agni Gautam Shah
Journal:  J Clin Diagn Res       Date:  2017-05-01

4.  Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.

Authors:  Andrea Nicolini; Gianna Tartarelli; Angelo Carpi; Maria Rita Metelli; Paola Ferrari; Loretta Anselmi; Massimo Conte; Piero Berti; Paolo Miccoli
Journal:  BMC Cancer       Date:  2006-11-20       Impact factor: 4.430

5.  The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer.

Authors:  A Nicolini; A Carpi; P Ferrari; L Anselmi; C Spinelli; M Conte; P Miccoli
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

6.  Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.

Authors:  Michiko Imamura; Takashi Morimoto; Takashi Nomura; Shintaro Michishita; Arisa Nishimukai; Tomoko Higuchi; Yukie Fujimoto; Yoshimasa Miyagawa; Ayako Kira; Keiko Murase; Kazuhiro Araki; Yuichi Takatsuka; Koshi Oh; Yoshikazu Masai; Kouhei Akazawa; Yasuo Miyoshi
Journal:  World J Surg Oncol       Date:  2018-02-12       Impact factor: 2.754

7.  Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Authors:  Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen
Journal:  Breast Cancer Res       Date:  2003-05-19       Impact factor: 6.466

8.  The Role of 18F-FDG PET/CT in Evaluating Elevated Levels of Tumor Markers in Breast Cancer.

Authors:  İnan Göktaş; Hakan Cayvarlı
Journal:  Mol Imaging Radionucl Ther       Date:  2018-02-01

Review 9.  Examining the evolving utility of 18FDG-PET/CT in breast cancer recurrence.

Authors:  Navid Djassemi; Shilpa Rampey; Juhi Motiani
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.